Heidi Mansour
Associate Professor, BIO5 Institute
Associate Professor, Clinical Translational Sciences
Associate Professor, Medicine
Associate Professor, Pharmaceutical Sciences
Primary Department
(520) 626-2768
Research Interest
Dr. Heidi M. Mansour, Ph.D., R.Ph. is a Tenured Associate Professor of Pharmaceutical Sciences in the College of Pharmacy with joint faculty appointments in the BIO5 Research Institute, the Clinical Translational Sciences graduate program in the UAHS, and the College of Medicine in the Division of Translational and Regenerative Medicine at The University of Arizona (UA) in Tucson, Arizona (USA). Dr. Mansour has a faculty member affiliation in the UA Institute of the Environment and is a research member the UA NCI Comprehensive Cancer Center Therapeutic Development Program. Dr. Mansour is Director of Pharmaceutics and Pharmacokinetics and Director of the Pharm.D./Ph.D. Dual Degree Program. She lectures in the B.S. Pharmaceutical Sciences undergraduate program, the Pharm.D. professional program and in the Pharmaceutics and Pharmacokinetics track of the graduate program at The University of Arizona. In addition to teaching, Dr. Mansour serves as Faculty Advisor in the Pharm.D./Ph.D. Dual-Degree Joint Program and Director of the Pharmaceutics and Pharmacokinetics track in the Pharmaceutical Sciences graduate program in The UA College of Pharmacy. As PI on multiple NIH, NSF, FDA, and pharmaceutical industrial grants, Dr. Mansour successfully leads multiple cutting-edge research projects. Her innovative research program has produced Assistant Professors who are employed at major research universities in the United States and in the Republic of S. Korea. In addition, her research program has produced Senior Research Scientists who are employed in major pharmaceutical companies in the United States. As Postdoc Mentor, Dr. Mansour has successfully mentored and trained over 10 Postdoctoral Research Scholars in my research program. As Major Professor, Dr. Mansour has successfully trained and graduated 3 doctoral graduate students with PhD degrees. Her mentoring experience extends as an active faculty mentor in the ATS Assembly Mentorship Program for several mentees in the ATS Assemblies each year. Dr. Mansour has published over 80 peer-reviewed scientific journal papers, 13 book chapters, 2 edited books, and over 100 scientific conference abstracts. She serves on the Editorial Advisory Boards of the The Royal Society of Chemistry Molecular Systems Design & Engineering, APhA/FIP Journal of Pharmaceutical Sciences, and Pharmaceutical Technology. Research in the Mansour GLP-approved labs focuses on the design, development, and optimization of advanced drug delivery systems and drug dosage forms. A systematic Quality-by-Design (QbD) approach includes in silico computational molecular modeling for predictive drug and formulation modeling, comprehensive physicocharacterization, advanced microscopy imaging, design of experiments (DOEs), formulation, USP/FDA-required in vitro performance studies, in vitro cellular studies, in vivo rodent animal studies for pharmacokinetics/pharmacodynamics/drug biodistribution, and translation medicine experiments. Dr. Mansour is an annual Faculty Instructor at ISAM (International Society of Aerosols in Medicine) Aerosol School, instructor in two online webinars on inhalation aerosol drug delivery, and instructor in Buchi Advanced Spray Drying short-courses. She was recently Co-Chair of the Drug Delivery: New Devices & Emerging Therapies Group in the International Society of Aerosols in Medicine (ISAM), and has been an expert member of NIH NICHD U.S. Pediatric Formulations Initiative New Drug Delivery Systems Aerosols Working Group for several years. Dr. Mansour currently serves on the Drug/Device Discovery and Development (DDDD) Committee of the American Thoracic Society (ATS). She regularly serves as an expert reviewer for scientific journals and grant funding agencies including NIH study sections, Department of Defense (DOD) study panels, National Science Foundation (NSF) study panels, AAAS, Catalent Drug Delivery Institute and international funding agencies such as the German-Israeli Foundation, German International Exchange Service (DAAD), Cochrane Airways Group of the National Health Service (London, England), Engineering and Physical Sciences Research Council (London, England), PRESTIGE Postdoc Fellowship Programme of the European Commission (Paris, France), and the Biomedical Innovation Program of the French National Research Agency (Paris, France). In addition to serving on NSF study panels, NIH study sections, and international study panels in the European Union and Great Britain, her innovative research program continuously attracts competitive funding awards from federal sources (NIH, NSF, FDA, DOD) and the pharmaceutical industry. In addition to lecturing in the BS Pharmaceutical Sciences undergraduate, Ph.D. graduate, and Pharm.D. professional programs, Dr. Mansour leads her research labs where she trains postdoctoral scholars, visiting scholars, visiting professors, graduate students, Pharm.D. student researchers, and physician-scientist (MD/PhD) fellows. As Major Professor and mentor, her research program has successfully graduated several Ph.D.s. Her innovative research program has produced Assistant Professors employed at research universities in the United States and in the Republic of S. Korea and Senior Research Scientists employed at major pharmaceutical companies in the United States. Dr. Mansour is an active, long-time member of several scientific organizations and elected member to honor societies, including the Sigma Xi Scientific Research Honor Society, Rho Chi Pharmaceutical Honor Society, and Golden Key International Honor Society. As a registered pharmacist for over 20 years, she earned her BS in pharmacy with honors and distinction, a PhD minor in advanced physical and interfacial chemistry (Department of Chemistry), and a PhD major in drug delivery/pharmaceutics (School of Pharmacy) from the University of Wisconsin-Madison. Also at the U.W.-Madison, she had been a Clinical Instructor for a few years. Having completed postdoctoral fellowships at the U.W.-Madison and at the University of North Carolina-Chapel Hill, she was awarded the UNC-Chapel Hill Postdoctoral Award for Research Excellence from the Office of the Vice-Chancellor, the AAPS Postdoctoral Fellow Award in Research Excellence, and the PhRMA Foundation Postdoctoral Fellowship award. As an Instructor, she served on the Graduate Faculty at UNC-Chapel Hill.


de la Vega, M. R., Dodson, M., Gross, C., Manzour, H., Lantz, R. C., Chapman, E., Wang, T., Black, S. M., Garcia, J. G., & Zhang, D. D. (2016). Role of Nrf2 and Autophagy in Acute Lung Injury. Current pharmacology reports, 2(2), 91-101.
BIO5 Collaborators
Clark Lantz, Heidi Mansour

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the clinical manifestations of severe lung damage and respiratory failure. Characterized by severe inflammation and compromised lung function, ALI/ARDS result in very high mortality of affected individuals. Currently, there are no effective treatments for ALI/ARDS, and ironically, therapies intended to aid patients (specifically mechanical ventilation, MV) may aggravate the symptoms. Key events contributing to the development of ALI/ARDS are: increased oxidative and proteotoxic stresses, unresolved inflammation, and compromised alveolar-capillary barrier function. Since the airways and lung tissues are constantly exposed to gaseous oxygen and airborne toxicants, the bronchial and alveolar epithelial cells are under higher oxidative stress than other tissues. Cellular protection against oxidative stress and xenobiotics is mainly conferred by Nrf2, a transcription factor that promotes the expression of genes that regulate oxidative stress, xenobiotic metabolism and excretion, inflammation, apoptosis, autophagy, and cellular bioenergetics. Numerous studies have demonstrated the importance of Nrf2 activation in the protection against ALI/ARDS, as pharmacological activation of Nrf2 prevents the occurrence or mitigates the severity of ALI/ARDS. Another promising new therapeutic strategy in the prevention and treatment of ALI/ARDS is the activation of autophagy, a bulk protein and organelle degradation pathway. In this review, we will discuss the strategy of concerted activation of Nrf2 and autophagy as a preventive and therapeutic intervention to ameliorate ALI/ARDS.

Hayes, D., Whitson, B. A., Ghadiali, S. N., Lloyd, E. A., Tobias, J. D., Mansour, H. M., & Black, S. M. (2015). Survival in Adult Lung Transplant Recipients Receiving Pediatric Versus Adult Donor Allografts. The Annals of thoracic surgery, 100(4), 1211-6.

Recent evidence showed that pediatric donor lungs increased rates of allograft failure in adult lung transplant recipients; however, the influence on survival is unclear.

Xiaojian, L. i., & Mansour, H. M. (2011). Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery. AAPS PharmSciTech (Impact Factor: 1.776), 12(4), 1420-1430.

PMID: 22038473;PMCID: PMC3225514;Abstract:

Novel advanced spray-dried inhalable trehalose microparticulate/ nanoparticulate powders with low water content were successfully produced by organic solution advanced spray drying from dilute solution under various spray-drying conditions. Laser diffraction was used to determine the volumetric particle size and size distribution. Particle morphology and surface morphology was imaged and examined by scanning electron microscopy. Hot-stage microscopy was used to visualize the presence/absence of birefringency before and following particle engineering design pharmaceutical processing, as well as phase transition behavior upon heating. Water content in the solid state was quantified by Karl Fisher (KF) coulometric titration. Solid-state phase transitions and degree of molecular order were examined by differential scanning calorimetry (DSC) and powder X-ray diffraction, respectively. Scanning electron microscopy showed a correlation between particle morphology, surface morphology, and spray drying pump rate. All advanced spray-dried microparticulate/nanoparticulate trehalose powders were in the respirable size range and exhibited a unimodal distribution. All spray-dried powders had very low water content, as quantified by KF. The absence of crystallinity in spray-dried particles was reflected in the powder X-ray diffractograms and confirmed by thermal analysis. DSC thermal analysis indicated that the novel advanced spray-dried inhalable trehalose microparticles and nanoparticles exhibited a clear glass transition (T g). This is consistent with the formation of the amorphous glassy state. Spray-dried amorphous glassy trehalose inhalable microparticles and nanoparticles exhibited vapor-induced (lyotropic) phase transitions with varying levels of relative humidity as measured by gravimetric vapor sorption at 25°C and 37°C. © 2011 American Association of Pharmaceutical Scientists.

Meenach, S. A., Anderson, K. W., Hilt, J. Z., McGarry, R. C., & Mansour, H. M. (2014). High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies. AAPS PharmSciTech (Impact Factor: 1.776), 15(6), 1574-87.

Inhalable lung surfactant-based carriers composed of synthetic phospholipids, dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG), along with paclitaxel (PTX), were designed and optimized as respirable dry powders using organic solution co-spray-drying particle engineering design. These materials can be used to deliver and treat a wide variety of pulmonary diseases with this current work focusing on lung cancer. In particular, this is the first time dry powder lung surfactant-based particles have been developed and characterized for this purpose. Comprehensive physicochemical characterization was carried out to analyze the particle morphology, surface structure, solid-state transitions, amorphous character, residual water content, and phospholipid bilayer structure. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) spectroscopy. PTX loading was high, as quantified using UV-VIS spectroscopy, and sustained PTX release was measured over weeks. In vitro cellular characterization on lung cancer cells demonstrated the enhanced chemotherapeutic cytotoxic activity of paclitaxel from co-spray-dried DPPC/DPPG (co-SD DPPC/DPPG) lung surfactant-based carrier particles and the cytotoxicity of the particles via pulmonary cell viability analysis, fluorescent microscopy imaging, and transepithelial electrical resistance (TEER) testing at air-interface conditions. In vitro aerosol performance using a Next Generation Impactor™ (NGI™) showed measurable powder deposition on all stages of the NGI and was relatively high on the lower stages (nanometer aerodynamic size). Aerosol dispersion analysis of these high-performing DPIs showed mass median diameters (MMADs) that ranged from 1.9 to 2.3 μm with excellent aerosol dispersion performance as exemplified by high values of emitted dose, fine particle fractions, and respirable fractions.

Hayes, D., Patel, A. V., Black, S. M., McCoy, K. S., Kirkby, S., Tobias, J. D., Mansour, H. M., & Whitson, B. A. (2015). Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. The Journal of thoracic and cardiovascular surgery [Impact Factor: 4.168], 150(3), 707-13.e2.

The influence of diabetes mellitus (DM) on survival in patients with cystic fibrosis (CF) before and after lung transplantation is not well studied.